Cumberland Pharmaceuticals Inc. CPIX

NAS: CPIX | ISIN: US2307701092   14/11/2024
1,200 USD (+1,69%)
(+1,69%)   14/11/2024

6 augustus 2024 · Cumberland Pharmaceuticals Reports 16% Sequential Revenue Growth in Second Quarter 2024 · Persbericht

30 juli 2024 · Cumberland Pharmaceuticals To Announce Second Quarter 2024 Financial Results · Persbericht

7 mei 2024 · Cumberland Pharmaceuticals Reports First Quarter 2024 Financial Results & Company Update · Persbericht

30 april 2024 · Cumberland Pharmaceuticals To Announce First Quarter 2024 Financial Results · Persbericht

2 april 2024 · New Report Supports Use Of Caldolor® As A Standard Of Care Across Patient Populations · Persbericht

5 maart 2024 · Cumberland Pharmaceuticals Reports Annual 2023 Financial Results · Persbericht

27 februari 2024 · Cumberland Pharmaceuticals To Announce Annual 2023 Financial Results · Persbericht

7 november 2023 · Cumberland Pharmaceuticals Reports Third Quarter 2023 Financial Results · Persbericht

31 oktober 2023 · Cumberland Pharmaceuticals To Announce Third Quarter 2023 Financial Results · Persbericht

10 oktober 2023 · New Vibatv® Pediatric Publication Highlights Its Safety In Patients 2 To 17 Years Of Age · Persbericht

8 augustus 2023 · Cumberland Pharmaceuticals Reports Revenue and Earnings Growth Second Quarter 2023 · Persbericht

1 augustus 2023 · Cumberland Pharmaceuticals To Announce Second Quarter 2023 Financial Results · Persbericht

26 juni 2023 · New Publication Supports The Use Of Caldolor® In Newborn Pediatric Patients · Persbericht

23 mei 2023 · Cumberland Pharmaceuticals Announces Fda Clearance Of Ind For New Treatment Of Idiopathic Pulmonary Fibrosis · Persbericht

15 mei 2023 · CALDOLOR® NOW FDA APPROVED FOR TREATMENT OF FEVER & PAIN IN INFANTS · Persbericht

9 mei 2023 · Cumberland Pharmaceuticals Reports First Quarter 2023 Financial Results & Company Update · Persbericht

2 mei 2023 · Cumberland Pharmaceuticals To Announce First Quarter 2023 Financial Results · Persbericht

7 maart 2023 · Cumberland Pharmaceuticals Reports 17% Revenue Growth For Full Year 2022 · Persbericht

28 februari 2023 · Cumberland Pharmaceuticals To Announce Annual 2022 Financial Results · Persbericht

8 november 2022 · Cumberland Pharmaceuticals Reports 41% Revenue Growth · Persbericht

Mijn selecties